×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Yahoo Finance
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report...
3 days ago
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Zacks Investment Research
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report...
3 days ago
Wilson Sonsini Advises Stoke Therapeutics on IP Matters Related to Upsized Public Offering
Wilson Sonsini
On March 28, 2024, Stoke Therapeutics, a biotechnology company focused on developing RNA-based medicines to treat severe diseases,...
1 month ago
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by...
3 weeks ago
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
markets.businessinsider.com
In the assessment of 12-month price targets, analysts unveil insights for Stoke Therapeutics, presenting an average target of $20.33, a high...
3 weeks ago
Stoke Therapeutics Stock: Dravet Data Sends Shares Soaring One For Watchlist (NASDAQ:STOK)
Seeking Alpha
Stoke Therapeutics' stock soars as positive data shows potential for their lead drug candidate, STK-001, in treating Dravet syndrome.
3 weeks ago
Stoke Therapeutics Shares Rise 80%, Co. Reports Data From Dravet Syndrome Study
MarketWatch
By Stephen Nakrosis Shares of Stoke Therapeutics were trading higher in Monday's after-hours session, following the release of data which...
1 month ago
Stoke's shares shoot up 90% as epilepsy drug slashes convulsive seizures
Fierce Biotech
Investors are stocking up on Stoke Therapeutics, sending the biotech's shares jumping over 90% in premarket trading on the back of positive...
1 month ago
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease ...
Yahoo Finance
BEDFORD, Mass., March 25, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying...
1 month ago
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by...
1 week ago